Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Syngenta R&D, Bracknell, Berkshire, UK.
SLAS Discov. 2020 Jul;25(6):618-633. doi: 10.1177/2472555220926160. Epub 2020 Jun 1.
CRISPR/Cas9 is increasingly being used as a tool to prosecute functional genomic screens. However, it is not yet possible to apply the approach at scale across a full breadth of cell types and endpoints. In order to address this, we developed a novel and robust workflow for array-based lentiviral CRISPR/Cas9 screening. We utilized a β-lactamase reporter gene assay to investigate mediators of TNF-α-mediated NF-κB signaling. The system was adapted for CRISPR/Cas9 through the development of a cell line stably expressing Cas9 and application of a lentiviral gRNA library comprising mixtures of four gRNAs per gene. We screened a 743-gene kinome library whereupon hits were independently ranked by percent inhibition, Z' score, strictly standardized mean difference, and statistic. A consolidated and optimized ranking was generated using Borda-based methods. Screening data quality was above acceptable limits (Z' ≥ 0.5). In order to determine the contribution of individual gRNAs and to better understand false positives and negatives, a subset of gRNAs, against 152 genes, were profiled in singlicate format. We highlight the use of known reference genes and high-throughput, next-generation amplicon and RNA sequencing to assess screen data quality. Screening with singlicate gRNAs was more successful than screening with mixtures at identifying genes with known regulatory roles in TNF-α-mediated NF-κB signaling and was found to be superior to previous RNAi-based methods. These results add to the available data on TNF-α-mediated NF-κB signaling and establish a high-throughput functional genomic screening approach, utilizing a vector-based arrayed gRNA library, applicable across a wide variety of endpoints and cell types at a genome-wide scale.
CRISPR/Cas9 技术越来越多地被用作进行功能基因组筛选的工具。然而,目前还不可能在广泛的细胞类型和终点范围内大规模应用该方法。为了解决这个问题,我们开发了一种新颖而强大的基于阵列的慢病毒 CRISPR/Cas9 筛选工作流程。我们利用β-内酰胺酶报告基因测定法来研究 TNF-α 介导的 NF-κB 信号转导的介质。通过开发稳定表达 Cas9 的细胞系和应用包含每个基因四种 gRNA 混合物的慢病毒 gRNA 文库,对该系统进行了 CRISPR/Cas9 的适应性改造。我们筛选了一个包含 743 个激酶基因的文库,然后通过抑制百分比、Z'得分、严格标准化均值差和 统计量对命中基因进行独立排名。使用基于博尔达的方法生成了综合和优化的排名。筛选数据质量高于可接受的标准(Z'≥0.5)。为了确定单个 gRNA 的贡献并更好地理解假阳性和假阴性,我们以单份格式对 152 个基因的一组 gRNA 进行了分析。我们强调了使用已知的参考基因和高通量、下一代扩增子和 RNA 测序来评估筛选数据质量。与混合物相比,使用单份 gRNA 进行筛选更成功地识别了已知在 TNF-α 介导的 NF-κB 信号转导中具有调节作用的基因,并且发现优于以前的基于 RNAi 的方法。这些结果增加了关于 TNF-α 介导的 NF-κB 信号转导的现有数据,并建立了一种高通量功能基因组筛选方法,该方法利用基于载体的阵列 gRNA 文库,可在广泛的终点和细胞类型中在全基因组范围内应用。